Regor’s selective approach attracts Roche
For $850m up front Roche gets to challenge Pfizer.
OncoC4 creates a bispecific buzz
But the reasons for its all-stock acquisition of AcroImmune seem more prosaic.
Looking for an ivonescimab encore
What similarly acting projects are still unpartnered?
One ricochet of the ivonescimab bullet
The small cap biotech Instil Bio tries to follow in Summit’s slipstream.
